<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29013">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02729025</url>
  </required_header>
  <id_info>
    <org_study_id>20130293</org_study_id>
    <secondary_id>2015-003731-35</secondary_id>
    <nct_id>NCT02729025</nct_id>
  </id_info>
  <brief_title>Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).</brief_title>
  <acronym>ANITSCHKOW</acronym>
  <official_title>A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9)
      inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Repatha (Evolocumab) on Lp(a), as measured by percent change from baseline at week 16 in target-to-background ratio of an index vessel by FDG-PET/CT in subjects with baseline Lp(a)&gt;=50mg/dL and Low-density lipoprotein-cholesterol&gt;=100mg/dL</measure>
    <time_frame>Week 16</time_frame>
    <description>The mentioned imaging method used will be fluorodeoxyglucose-positron emission tomography/ computed tomography (FDG-PET/CT);</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Repatha (Evolocumab) on Lp(a), as measured by percent change in Lp(a) from baseline at week 16 in subjects with baseline Lp(a)&gt;=50mg/dL and Low-density lipoprotein-cholesterol (LDL-C)&gt;=100mg/dL</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Repatha (Evolocumab) on LDL-C, as measured by percent change in LDL-C from baseline at week 16 in subjects with baseline Lp(a)&gt;=50mg/dL and LDL-C&gt;=100mg/dL</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Repatha (Evolocumab) on Apolipoprotein B (ApoB), as measured by percent change in ApoB from baseline at week 16 in subjects with baseline Lp(a)&gt;=50mg/dL and LDL-C&gt;=100mg/dL</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4 to Repatha (Evolocumab) in subjects with baseline Lp(a)&gt;=50mg/dL and LDL-C&gt;=100mg/dL</measure>
    <time_frame>Permanently throughout the study duration until EOS, an average of 1 year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Subjects With Hyperlipidemia, Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Repatha (Evolocumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repatha (Evolocumab) subcutaneous injection every 4 weeks (QM) using 3 auto injector (AI) Pen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repatha (Evolocumab) Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Repatha (Evolocumab) Matching Placebo subcutaneous injection every 4 weeks (QM) using 3 auto injector (AI) Pen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repatha (Evolocumab)</intervention_name>
    <description>Dose of subcutaneous Repatha (Evolocumab) every 4 weeks (QM) using 3 auto injector (AI) Pen</description>
    <arm_group_label>Repatha (Evolocumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose of subcutaneous Repatha (Evolocumab) Matching Placebo every 4 weeks (QM) using 3 auto injector (AI) Pen</description>
    <arm_group_label>Repatha (Evolocumab) Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting lipoprotein(a) (Lp(a)) 50mg/dL or more at screening 1

          -  Fasting Low-density lipoprotein-cholesterol (LDL-C) 100mg/dL or more at screening 1

          -  Lipid lowering therapy including statin dose unchanged for at least 8 weeks prior to
             screening

          -  Target-to-background ratio (TBR) max higher than 1.6 (either right, left carotid or
             thoracic aorta) on fluorodeoxyglucose-positron emission tomography/computed
             tomography (FDG-PET/CT).

        Exclusion Criteria:

          -  Currently receiving, or less than 4 weeks since receiving, treatment in another
             investigational device or drug study(ies), or participating in other investigational
             procedures

          -  Known diagnosis of diabetes mellitus or screening fasting serum glucose ≥ 126 mg/dL
             or hemoglobin A1C (HbA1C) ≥ 6.5%

          -  Subject with a history of homozygous familial hypercholesterolemia

          -  History of a Cardiovascular event

          -  Subject currently undergoing lipid apheresis

          -  Known contraindications or limitations to FDG-PET/ CT (scanner weight limit, devices
             that can cause image artifacts, or carotid/aortic stents/grafts

          -  Subject has had exposure to investigational drugs targeting Lp(a) within the last 12
             months, prior to Screening

          -  Other Exclusion Criteria May Apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waalwijk</city>
        <zip>5141 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 12, 2016</lastchanged_date>
  <firstreceived_date>March 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibition</keyword>
  <keyword>Arterial Wall Inflamation</keyword>
  <keyword>Elevated lipoprotein a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
